Hee Yi

Hee Yi

Auto-generated profile, based on publicly available information

Hee Yi

Veterinary Drugs and Biologics Division, Animal and Plant Quaratine Agency (APQA), Gimcheon-Si, Republic of Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
SKSeok-Jin Kang
Seok-Jin Kang
YPYoung-Il Park
Young-Il Park
SHSo-Ryeon Hwang
So-Ryeon Hwang
HYHee Yi
Hee Yi
NTNga Tham
Nga Tham
HKHwan-Goo Kang
Hwan-Goo Kang
Pluripotent stem cells (PSCs) such as embryonic stem cells and induced pluripotent stem cells are promising target cells for cell regenerative medicine together with recently advanced technology of in-vitro differentiation. However, residual undifferentiated stem cells (USCs) during in-vitro differentiation are considered a potential risk for development of cancer cells and nonspecific lineage cell types. In this study we observed that USCs still exist during hepatic differentiation, consequently resulting in poor quality of the hepatic population and forming teratoma in vivo. Therefore, we hypothesized that effectively removing USCs from in-vitro differentiation could improve the quality of the hepatic population and guarantee safety from risk of teratoma formation. Human PSCs were differentiated to hepatocytes via four steps. YM155, a known BIRC5 inhibitor, was applied for removing the residual USCs on the hepatic differentiation. After YM155 treatment, hepatocyte development was evaluated by measuring gene expression, immunostaining and hepatic functions at each stage of differentiation, and forming teratomas were confirmed by cell transplantation with or without YM155. The selected concentrations of YM155 removed USCs (NANOG+ and OCT4+) in a dose-dependent manner. As a result, expression of endodermal markers (SOX17, FOXA2 and CXCR4) at stage II of differentiation and hepatic markers (ALB, AFP and HNF4A) at stage III was up-regulated by YM155 treatment as well as the hepatic population (ALB+), and functions (ALB/urea secretion and CYP450 enzyme activity) were enhanced at the final stage of differentiation (stage IV). Furthermore, we demonstrated that NANOG and OCT4 expression remaining until stage III (day 15 of differentiation) completely disappeared when treated with YM155 and teratoma formation was effectively prevented by YM155 pretreatment in the in-vitro study. We suggest that the removal of USCs using YM155 could improve the quantity and quality of induced hepatocytes and eliminate the potential risk of teratoma formation.

1 January 2020 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
BJByuns-Suk Jeon
Byuns-Suk Jeon
SLSoo-Ho Lee
Soo-Ho Lee
SHSo-Ryeon Hwang
So-Ryeon Hwang
HYHee Yi
Hee Yi
JBJi-Hyun Bang
Ji-Hyun Bang
HKHyun-Ok Ku
Hyun-Ok Ku
Jeon BS, et al. J Vet Sci. 2019 Oct;21:e81. https://doi.org/10.4142/jvs.2020.21.e81

1 June 2024 in Journal of Biomedical and Translational Research
Verified
Journal Article
Open access
PDF file
NKNam-Ju Kim
Nam-Ju Kim
JBJi-Hyun Bang
Ji-Hyun Bang
HYHee Yi
Hee Yi
HKHyun-Ok Ku
Hyun-Ok Ku
JJoong Sun Kim
Joong Sun Kim
BJByuns-Suk Jeon
Byuns-Suk Jeon
Journal of Biomedical and Translational Research

1 January 2019 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
JBJi-Hyun Bang
Ji-Hyun Bang
HKHyun-Ok Ku
Hyun-Ok Ku
HKHwan-Goo Kang
Hwan-Goo Kang
HKHyobi Kim
Hyobi Kim
SKSoohee Kim
Soohee Kim
HYHee Yi
Hee Yi
Bang JH, et al. J Vet Sci. 2019 Mar;20(2):e9. https://doi.org/10.4142/jvs.2019.20.e9

1 January 2021 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
BJByuns-Suk Jeon
Byuns-Suk Jeon
HYHee Yi
Hee Yi
HKHyun-Ok Ku
Hyun-Ok Ku
Jeon BS, et al. J Vet Sci. 2020 Dec;22:e6. https://doi.org/10.4142/jvs.2021.22.e6